Nanoparticle-based vaccine / SARS-CoV-2
- Funded by ANR
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
ANRPrincipal Investigator
Isabelle DIMIERPOISSONResearch Location
FranceLead Research Institution
Université de ToursResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
The NANO-SARS-CoV-2 project, coordinated by Isabelle Dimier-Poisson (UMR 1282 - INRAE - University of Tours), concerns the development of an anti-SARS-CoV-2 vaccine platform made up of biocompatible nanoparticles encapsulating the antigenic candidates S and N of SARS-CoV-2, or associating viral-like particles (VLP) of SARS-CoV-2, in order to induce humoral and cellular immune responses at the level of the mucosal and systemic compartments. It aims to deliver a nanoparticulate mucosal vaccine candidate against SARS-CoV-2.